Antipsychotics for Schizophrenia: Benefits, Side Effects, and Monitoring
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Antipsychotic medications are a central evidence-based treatment for schizophrenia. For many people, they reduce hallucinations, delusions, and disorganized thinking during an acute episode and lower the chance of relapse after stabilization. Their risks deserve equally careful attention: weight and metabolic changes, movement disorders, sedation, hormonal effects, sexual difficulties, cardiovascular effects, and individual reactions can significantly influence daily life. The clinical goal is sustained benefit with tolerable burdens and reliable physical-health monitoring, supported by the person's own priorities. American Psychiatric Association guideline; NICE guideline CG178.
This guide explains what antipsychotics can and cannot accomplish for an established schizophrenia diagnosis; how different medications compare; what clinicians assess before starting, during an initial trial, and over years of care; and when treatments such as long-acting injectables or clozapine become relevant. Medication selection, dose adjustments, stopping, and switching require individualized professional evaluation. An antipsychotic prescription, or even a favorable response to one, does not establish a schizophrenia diagnosis: psychosis can occur in several psychiatric, neurological, substance-associated, and medical conditions. For the broader diagnostic and recovery framework, see Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery.
What are antipsychotic medications?
Antipsychotics are prescription medications used to treat psychotic symptoms and certain other clinical conditions. In schizophrenia, treatment generally targets acute psychotic symptoms and helps prevent their return after a successful response. Many older and newer medications affect dopamine D2 receptor signaling; several also affect serotonin and other receptors, which helps explain important differences in clinical effects and adverse events. Antipsychotics are often called neuroleptics in older writing. That historical label does not describe the full diversity of currently available drugs.
A meaningful medication outcome includes more than a change on a symptom-rating scale. Clinicians and patients should examine whether the person sleeps more consistently, experiences less frightening or intrusive psychotic symptoms, can concentrate or participate in relationships and activities more readily, and feels able to direct everyday life. Sedation that makes someone appear quieter is not by itself proof of an adequate antipsychotic response. Likewise, a return of energy after a medication adjustment is not automatically evidence that schizophrenia has resolved.
What antipsychotics treat—and what they may leave unchanged
Hallucinations, delusions, and disorganized thinking
The strongest direct drug evidence concerns reducing positive psychotic symptoms: hallucinations, delusions, and disturbances of thought or behavior during acute schizophrenia. A 2019 network meta-analysis in The Lancet31135-3) compared 32 oral agents, finding broad efficacy over placebo with meaningful differences in tolerability and some efficacy outcomes. A 2026 network meta-analysis in The Lancet02365-7), incorporating dopamine-targeting agents and the newer muscarinic treatment, similarly found symptom benefits over placebo across drugs evaluated, while emphasizing the limits of cross-drug rankings and the need to weigh adverse effects.
Improvement may begin during the early weeks, but response varies by person, symptom, medication, prior exposure, dose and adherence. Some people experience substantial reductions in symptoms, some have a partial response, and others need reassessment. NICE recommends treating an initial prescription as an explicit therapeutic trial with documented goals and generally evaluating an appropriately dosed trial over approximately four to six weeks. That timetable is a guideline for assessment, not permission to tolerate dangerous reactions or a reason to ignore early response and emerging adverse effects. NICE CG178.
Negative symptoms and cognitive difficulties
Schizophrenia can also involve reduced motivation, limited emotional expression, social withdrawal and difficulties with attention, working memory, or planning. These problems may reflect primary illness dimensions, depression, social deprivation, untreated psychosis, poor sleep, medication effects, or more than one cause. Antipsychotics can improve some secondary negative symptoms when distressing positive symptoms improve, but they have limited and inconsistent effects on persistent primary negative symptoms and cognitive impairments. Increasing the dose solely because someone still feels unmotivated may increase side-effect burden without addressing the cause. Functional assessment and psychosocial treatment remain important. NIMH schizophrenia overview; APA schizophrenia guideline.
How effective are antipsychotics for schizophrenia?
Acute symptom reduction
Randomized trials show that antipsychotic medications, on average, improve acute schizophrenia symptoms more than placebo. Comparative estimates describe outcomes for groups; they do not predict which medicine will be best for a particular person. Differences in trial populations, previous episodes, dose, study duration, outcome definitions and incomplete data make rigid league tables especially misleading. In the 2026 network meta-analysis, some medicines showed larger estimated reductions in symptoms than others, but confidence in many between-drug differences was only low to moderate. The Lancet 2026 network meta-analysis02365-7).
Relapse prevention and hospitalization
Maintenance treatment has a particularly substantial evidence base. An updated Cochrane review pooled 75 randomized trials involving 9,145 participants. At seven to twelve months, relapse occurred in approximately 24% of participants assigned to maintenance medication versus 61% assigned to placebo or discontinuation protocols across the relevant trials; hospitalization was approximately 7% versus 18%. These numbers describe those study populations and designs, not a personal probability, a lifetime forecast, or the effects of every specific drug.
The review also found greater risks of certain adverse effects with medication, including movement problems, sedation and weight gain. Many studies were relatively short, and long-term functional and mortality outcomes remained less certain. The practical interpretation is a recurring treatment review that considers prevention of relapse together with tolerability, life circumstances and the person's preferences. Ceraso et al., Cochrane 2020.
Functioning and recovery
Successful care also addresses quality of life, physical health, housing, education, work, relationships and self-directed goals. Medication can make other interventions more accessible by reducing severe symptoms. It does not substitute for psychological care, family support where welcome, supported employment, coordinated services, or recovery-oriented planning. Clinical guidelines favor integrating medication with appropriate psychosocial interventions rather than measuring success exclusively by symptom suppression. VA/DoD 2023 guideline; NICE CG178.
First-generation and second-generation antipsychotics
The traditional first-generation group includes haloperidol and chlorpromazine. Commonly prescribed second-generation drugs include aripiprazole, brexpiprazole, cariprazine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone. The categories are historically useful, but receptor profiles and clinical effects overlap. Second-generation does not mean universally safer or more effective; some agents have particularly substantial metabolic effects, while others produce more movement-related or prolactin-related problems. Huhn et al., 201931135-3).
In broad terms, strong dopamine D2 blockade can bring a higher risk of drug-induced parkinsonism, akathisia, dystonia, and prolactin elevation. Medicines with appreciable antihistamine or other receptor activity may be more sedating or associated with greater appetite and weight gain. These are class-level tendencies with drug-specific exceptions; actual risks depend on the medicine, dose, combinations and individual susceptibility. For that reason, comparing medications by their specific risk profile is more informative than simply choosing by generation. APA guideline.
How do commonly used antipsychotics differ?
Aripiprazole, brexpiprazole, and cariprazine
These agents have dopamine partial-agonist properties and may have a lower average burden of some metabolic or prolactin effects than higher-risk alternatives. Akathisia—an uncomfortable internal need to move—can be a significant difficulty, particularly with some partial agonists. Agitation, insomnia or subjective restlessness require active assessment rather than being automatically attributed to psychiatric symptoms. Selection also depends on interactions, formulation, past experience and the person's treatment goals. Comparative findings should be applied to the individual medication and trial setting. The Lancet 2026 analysis02365-7).
Risperidone and paliperidone
Both have established efficacy for psychotic symptoms and are available in different formulations, including long-acting injections for appropriate patients. Prolactin elevation and associated sexual or reproductive symptoms, alongside movement symptoms at some exposures, deserve attention. Their relationship does not mean they are interchangeable: renal function, formulations, interaction patterns and prescribing information matter. APA guideline; NICE CG178.
Olanzapine and quetiapine
Olanzapine has substantial evidence of antipsychotic efficacy but is associated with comparatively high average weight gain and metabolic risk. Quetiapine can cause prominent sedation and orthostatic hypotension, with metabolic changes also relevant. Neither sedation nor appetite increase should be confused with treatment effectiveness. For an individual with diabetes risk, obesity, disabling daytime sleepiness or cardiovascular vulnerability, these differences can meaningfully affect the choice. Huhn et al., 201931135-3); NICE monitoring guidance.
Haloperidol and other older agents
Haloperidol remains an effective antipsychotic in appropriately selected situations. Its movement-related adverse-effect profile can be a deciding limitation, especially as exposure increases. Low- and mid-potency older medications may produce sedation, orthostasis or anticholinergic effects in differing degrees. A drug's age is not sufficient evidence that it is unsuitable; individualized benefit and observed adverse effects matter. APA guideline.
Clozapine
Clozapine occupies a particular place in schizophrenia treatment, with guideline support after inadequate response to two suitable antipsychotic trials. It also has evidence and guideline recommendations for some patients with persistent substantial suicide risk despite other treatment. It requires specialized medical oversight because of severe neutropenia, myocarditis or cardiomyopathy, seizures, constipation that can progress to serious bowel complications, substantial metabolic effects, sedation and other risks. Its benefit in treatment-resistant illness can be considerable, but the balance requires comprehensive monitoring. APA guideline; NICE treatment resistance guidance.
Xanomeline–trospium (Cobenfy): the newer mechanism
In September 2024, the U.S. FDA approved xanomeline–trospium for adults with schizophrenia. Unlike traditional dopamine-receptor blockers, the combination acts through muscarinic signaling and has a different adverse-effect profile. Short-term placebo-controlled studies supported symptom improvement, while longer-term and direct head-to-head comparisons have important evidence gaps. Its possible advantages should be evaluated alongside nausea, vomiting, gastrointestinal effects, urinary retention, increased heart rate, potential liver injury, and its specific contraindications. It does not belong in a simple 'newer means safer' ranking. FDA approval notice; The Lancet 2026 comparative review02365-7).
How is an antipsychotic chosen for an individual person?
Clinical selection begins with a confirmed working diagnosis and a clear target: relief of an acute episode, sustained prevention of relapse, or a reassessment after incomplete benefit or adverse effects. Important inputs are previous response; specific side-effect history; metabolic, cardiovascular, neurological, renal and liver conditions; pregnancy-related considerations where relevant; age; other prescribed and nonprescribed substances; interaction risks; availability and cost; and whether an oral or long-acting formulation is practical and preferred. The person's priorities—including body image, sexual functioning, alertness, mobility and ability to work—are clinical information, not afterthoughts. NICE shared-decision guidance.
There is no single best first antipsychotic for every person with schizophrenia. A medication with strong average efficacy may be a poor match for someone with a particularly high susceptibility to its adverse effects. A theoretically favorable side-effect profile may not offset an individual's previous ineffective trial. The treating team should document why the selected option fits the situation and agree in advance what counts as benefit, what reactions trigger review, and when follow-up will occur. APA guideline.
Beginning treatment: baseline assessment
A baseline appointment should establish the person's symptoms and functional goals, previous medication response, current medical conditions and all relevant prescriptions, over-the-counter medicines, supplements and substance exposures. The team should also examine physical-health risks and symptoms that may already exist before medication begins; otherwise a new movement symptom, weight change or fatigue could be misattributed. An initial examination is particularly important in first-episode presentations because a new psychosis syndrome can arise from medical or substance-related causes. VA/DoD first-episode guidance.
NICE specifies baseline measurement of weight, waist circumference, pulse and blood pressure, fasting blood glucose or HbA1c, a lipid profile, prolactin, existing movement disorders, nutrition, diet and physical activity. An electrocardiogram is recommended when indicated by the particular drug's product information, cardiovascular findings or history, or inpatient admission. Other tests—including blood counts, electrolytes, kidney or liver tests, pregnancy-related evaluation, and additional investigations—are selected according to the person, medicine and clinical situation, rather than ordered identically for everyone. NICE CG178, section 1.3.6.
Monitoring schedule: what to check and when
Weight and metabolic health
For adults, NICE specifies recording weight weekly for the first six weeks, then at 12 weeks, one year and at least annually. It recommends checking waist circumference annually, pulse and blood pressure at 12 weeks and at one year and annually thereafter, and fasting glucose or HbA1c plus lipids at 12 weeks, at one year and annually. Baseline measurements come first. Earlier or more frequent checks may be clinically appropriate when weight is changing rapidly, diabetes is present or emerging, cardiovascular risk is high, or a specific medication requires closer attention. NICE adult schizophrenia monitoring schedule.
This schedule is a useful clinical reference, not a universal substitute for local guidance, laboratory trends or medication-specific labeling. Monitoring should continue over time, including when psychiatric symptoms are stable; treatment success never makes elevated glucose, blood pressure or dyslipidemia irrelevant. Clinical teams should identify clearly whether psychiatry, primary care or another service will order tests, review results and act on abnormalities. NICE recommends specialist-service responsibility during at least the first 12 months or until stability, with a coordinated handover afterward. NICE CG178.
Movement symptoms and tardive dyskinesia
At baseline and repeatedly during follow-up, clinicians should ask about tremor, stiffness, slowness, internal restlessness, sustained abnormal muscle contractions, and involuntary movements. A structured scale such as the Abnormal Involuntary Movement Scale (AIMS) may help identify and document tardive dyskinesia. Monitoring needs to be proactive because a person may normalize a slowly developing movement problem or find it difficult to describe. The treatment response to different movement disorders varies, making correct identification crucial. APA guideline.
Prolactin, sexual and reproductive symptoms
Risperidone, paliperidone and some other antipsychotics can increase prolactin and contribute to menstrual changes, breast symptoms, sexual dysfunction or other hormonal effects. Clinicians should invite discussion of these symptoms sensitively and check prolactin or related investigations when clinically indicated, alongside the baseline testing specified by NICE. A normal result on one occasion does not replace subsequent symptom assessment. NICE CG178.
Cardiovascular, sedation, and general medical review
Blood pressure changes, dizziness on standing, pulse changes, palpitations and fainting can be particularly relevant around initiation or dose adjustments. QT interval concerns and ECG needs depend on the medication, cardiac history, interacting drugs and other risk factors. Clinicians should also ask about constipation, urinary problems, daytime alertness, sleep, falls, swallowing or respiratory symptoms and capacity for safe daily activities. Monitoring has to reflect the actual agent rather than being limited to a generic laboratory checklist. NICE CG178.
Antipsychotic side effects explained
Weight gain, high blood sugar, and cholesterol changes
Appetite and weight can change soon after an antipsychotic is started. For some people the gain is rapid and substantial, contributing to insulin resistance, diabetes or lipid abnormalities. Metabolic effects also differ greatly between drugs. Waiting until a severe problem develops misses the opportunity for earlier prevention. A 2025 consensus guideline in Schizophrenia Bulletin found evidence that clinician-prescribed metformin can attenuate antipsychotic-associated weight gain in selected situations; whether it is appropriate requires assessment of kidney function, contraindications, interactions and the person's preferences. Lifestyle, nutritional and activity support remain important and should avoid stigma or blame. Carolan et al., 2025.
Akathisia, dystonia, parkinsonism, and tardive dyskinesia
Akathisia is a distressing feeling of inner restlessness often accompanied by pacing, shifting position or difficulty sitting still. It may be mistaken for anxiety or worsening agitation. Dystonia causes sustained or repeated involuntary muscle contractions, sometimes acutely affecting the neck, eyes, jaw or other muscles. Drug-induced parkinsonism may cause stiffness, tremor and slowed movement. Tardive dyskinesia involves involuntary movements that can persist even after a medication has changed; risk varies with cumulative exposure and susceptibility. Different problems require different responses, which may include clinician-supervised dose changes, switching agents or specific treatments. APA recommendations.
Sudden muscle spasm affecting breathing or swallowing, severe rigidity with fever, or a rapid deterioration in consciousness demands emergency assessment. Such presentations require evaluation for serious medication reactions or other acute medical conditions. These situations should never be handled by experimenting with home dose changes. NICE CG178.
Sedation, fatigue, and orthostatic effects
Drowsiness can interfere with learning, work, parenting, relationships and driving. Some people value an improvement in sleep early in treatment, while others experience sedation as debilitating. Orthostatic hypotension may cause dizziness when standing, with added concerns about falls or fainting. These effects merit a review of timing, co-medications, hydration, medical comorbidity and the overall regimen; no one should treat sedation as a required price of controlling psychosis. Huhn et al., 201931135-3).
Sexual functioning, menstrual changes, and emotional experience
Changes in libido, arousal, orgasm, menstruation or breast symptoms may be related to prolactin, sedation, mood, the underlying illness or combinations of factors. Some people also describe feeling emotionally flattened or cognitively slowed, experiences that should be examined rather than dismissed. The clinical task is to investigate causes while protecting privacy and supporting treatment goals. Telling the team about a side effect is clinically useful information and should lead to a proportionate response. NICE shared decisions.
Rare but important severe adverse reactions
Neuroleptic malignant syndrome is an uncommon emergency that can include marked rigidity, high temperature, autonomic disturbance and altered mental status. Clozapine carries distinct risks of severe neutropenia, myocarditis and severe gastrointestinal hypomotility. Specific agents can pose risks involving liver function, seizures, urinary retention or cardiac conduction. Symptoms such as chest pain, severe shortness of breath, fainting, fever with marked stiffness, inability to pass urine, or severe constipation with abdominal pain or vomiting deserve urgent medical attention. FDA clozapine safety communication; FDA xanomeline–trospium communication.
Clozapine: special effectiveness and special monitoring
For treatment-resistant schizophrenia, guidelines recommend considering clozapine after two antipsychotic trials with adequate duration, dose and actual exposure have failed to produce sufficient benefit. The evaluation first checks the diagnosis, adherence, physical and substance-related factors, and whether symptoms were evaluated over suitable periods. Clozapine may also be indicated when substantial risk of suicide attempts persists despite other treatments. Patients considering it need an explicit discussion of likely benefit, laboratory requirements, constipation prevention and safety warning signs. NICE CG178; APA guideline.
A notable U.S. regulatory change occurred in 2025: the FDA eliminated the clozapine Risk Evaluation and Mitigation Strategy (REMS), effective June 13, 2025. This ended compulsory REMS enrollment and ANC reporting as a dispensing condition. It did not eliminate the medical risk of severe neutropenia or the need for ANC blood monitoring according to the current prescribing information. Infections, fever, sore throat and other warning signs require assessment. The FDA specifically continues to recommend ANC monitoring under the labeling; clinical practice must also account for myocarditis, serious constipation, metabolic changes and other risks. FDA announcement, August 27, 2025.
Oral tablets versus long-acting injectable antipsychotics
Long-acting injectable formulations deliver antipsychotic medication on an extended schedule, reducing the need for daily pills. They can be a valuable preference-based option or help when regular oral doses are difficult to maintain. They remain prescription antipsychotics with medication-specific adverse effects, necessary monitoring, administration schedules and sometimes oral overlap or tolerability requirements. The ability to receive an injection does not imply a person's lack of agency; choice and informed consent matter. APA guideline.
A large 2021 comparative meta-analysis found an association between long-acting injectables and lower hospitalization or relapse risk across randomized, cohort and pre-post study designs, while noting differences in bias and effect estimates. Such results support discussing injectables as an option, without promising superior outcomes for every person or formulation. A dedicated analysis of formulation-specific evidence deserves its own article rather than being folded into a universal drug ranking.
How long should someone take an antipsychotic?
Duration depends on the number and severity of previous episodes, the course of symptoms, the impact of relapse, drug tolerability, personal circumstances and the person's informed goals. Continuing a medication that has helped prevent recurrence is often supported by evidence, but reviews should remain active rather than automatic. There is no single lifetime duration rule for every person with schizophrenia. The risk of symptom return following reduction or discontinuation needs explicit discussion and an agreed early-warning and support plan. Cochrane maintenance review.
Stopping suddenly can create withdrawal-related problems or contribute to recurrence, and changes should be planned with the prescriber. The open-label RADAR randomized trial studied guided dose reduction or discontinuation compared with maintenance in people with recurrent psychotic disorders; it underscores why long-term decisions involve real tradeoffs between adverse effects, relapse and functioning. A wish to reduce burden deserves careful collaborative assessment, not dismissal or an improvised self-taper.
What if the first medication does not work?
Before judging a trial unsuccessful, a clinician checks the target symptoms, whether the diagnosis and medical evaluation remain appropriate, whether the medicine was taken and absorbed as expected, dose and treatment duration, interactions, side effects that limit exposure, and relevant environmental or substance factors. If benefit is insufficient or adverse effects unacceptable, a switch may be reasonable. Overlapping medications during a supervised switch can sometimes be necessary, but maintaining several antipsychotics routinely is not a first-line solution. NICE recommendations on non-response and combinations.
Two adequate failed trials raise the question of treatment-resistant schizophrenia and clozapine eligibility rather than an endless sequence of similar medication changes. Persistent hallucinations or distress may also warrant condition-specific psychological treatment, family psychoeducation with consent, support for substance use or sleep problems, and assistance with daily functioning. Care planning remains individualized and recovery-oriented. APA guideline.
First-episode psychosis and diagnostic uncertainty
First-episode psychosis is a presentation and care pathway, not necessarily a confirmed schizophrenia diagnosis. Assessment should consider mood episodes, substance and medication exposures, acute medical conditions, delirium, neurologic illness and other causes. The early-intervention approach prioritizes access to coordinated services, collaboration and careful treatment choices. NICE recommends offering oral antipsychotics alongside psychological interventions for first-episode psychosis, with individualized monitoring and shared decisions. NICE first-episode section; VA/DoD 2023.
Clinical high-risk or attenuated psychotic experiences are a different situation. A risk-state assessment does not confirm schizophrenia, and some people will never develop a psychotic disorder. NICE advises against offering antipsychotic medication merely to prevent psychosis in people deemed at increased risk. A person facing sudden severe confusion, seizures, high fever, major consciousness changes or catatonic signs needs timely medical assessment rather than a self-diagnosis from an article. NICE prevention guidance.
What medications cannot replace
Medication is one part of a broader clinical program. Cognitive behavioral therapy for psychosis, individualized family work, supported education or employment, smoking and physical-health support, culturally responsive communication and coordinated specialty care may make important contributions. Addressing social isolation, trauma-related distress and treatment preferences also matters. A treatment plan should support agency, chosen relationships and practical functioning alongside symptom control. NICE CG178; NIMH overview.
Shared decision-making: practical questions for appointments
A medication review becomes more useful when it is tied to specific questions: Which symptoms are we treating, and what changes would show benefit? What has worked or been difficult previously? What are the likely metabolic, movement, sexual, cognitive, cardiovascular and sleep-related effects of this drug? Which baseline tests are needed, and who will review the results? When is the first follow-up? What should prompt an earlier call? Which alternatives exist if benefit is incomplete? How will daily activities, physical health and personally meaningful goals be evaluated?
Patients can ask the prescriber to summarize the reasoning for the chosen drug, the monitoring schedule, and what will happen if the first option is ineffective or intolerable. Family or supporters can participate if the person wants their involvement. The principle is collaborative clinical decision-making that respects meaningful preferences while making risks and uncertainties understandable. NICE shared-choice recommendation.
When to seek prompt or emergency medical help
Prompt clinical contact is important after new restlessness, tremor, markedly increased thirst or urination, fainting, rapid substantial weight change, persistent constipation, concerning sexual or hormonal effects, or a return of psychotic symptoms. Serious presentations such as high fever with severe stiffness, confusion and autonomic disturbance; suspected severe drug allergy; chest pain or breathing difficulty; severe constipation with vomiting or abdominal pain; or acute inability to urinate require emergency evaluation. For clozapine users, fever or infection symptoms have particular importance. FDA clozapine safety notice.
Acute risk of suicide, severe self-neglect, threatening command experiences, catatonia, and rapidly changing mental status call for urgent professional assessment. These warning signs require evaluation in their clinical context; they do not make every hallucination an emergency. If immediate safety is at risk, contact local emergency services or seek emergency care. NIMH: Understanding Psychosis.
Frequently asked questions
Are antipsychotics always necessary for schizophrenia?
They are a guideline-recommended core treatment for established schizophrenia, especially for acute psychotic symptoms and prevention of recurrence after response. An individual plan must weigh benefits, adverse effects, preferences and other treatments, with clinician-guided review. The decision changes when the diagnosis is uncertain or the person is being assessed for a clinical high-risk state. APA guideline; NICE CG178.
Which antipsychotic has the fewest side effects?
No medication has the fewest side effects across every category. One may cause less average weight gain but more akathisia; another may cause more sedation or prolactin-related symptoms. The appropriate comparison is a specific drug's anticipated and observed effects against the person's medical history and priorities. Huhn et al., 201931135-3).
How quickly do antipsychotics work?
Some improvement may appear early, while evaluating a full initial therapeutic trial takes longer and depends on adequate exposure and tolerability. NICE describes a four-to-six-week appropriately dosed trial for assessment; an urgent adverse event must be addressed immediately. A person should not independently raise the dose because improvement is incomplete after a few days. NICE CG178.
Can antipsychotics cause permanent movement problems?
Tardive dyskinesia can persist after a medication change or discontinuation, although outcomes vary. Monitoring and early recognition are important. Other movement effects such as acute dystonia, drug-induced parkinsonism or akathisia require different evaluation and management. APA guideline.
Can weight gain from antipsychotics be prevented?
Risk can be reduced through suitable drug choice, baseline and follow-up monitoring, relevant nutritional and physical-activity support, and in selected cases clinician-prescribed preventive treatments. Evidence-informed metformin strategies exist, but they need individualized assessment. No strategy guarantees complete prevention. Carolan et al., 2025.
Does the removal of clozapine REMS mean blood monitoring is no longer needed?
No. U.S. REMS enrollment and required ANC reporting for dispensing ended in 2025, but the FDA continues to recommend ANC monitoring according to the drug's prescribing information because severe neutropenia remains a potentially life-threatening risk. FDA drug safety communication.
Are long-acting injections more powerful than pills?
Their principal advantage is an alternative delivery schedule that may improve treatment continuity for some people. Medication, dose, formulation, individual response and preferences determine the outcome; injectables should not be described as universally more powerful. LAI comparative review.
Can someone stop antipsychotics after feeling well?
Feeling better may reflect an effective treatment response. Maintenance therapy reduces relapse in randomized trials, while treatment burden may still justify a careful review. Decisions about reduction or discontinuation should involve the prescriber, an agreed plan, monitoring and support. Abrupt self-directed cessation can be harmful. Cochrane review.